Donepezil is better tolerated than rivastigmine in mild-to-moderate Alzheimer's disease

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1258, 2000-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rivastigmine Transdermal Patch Skin Tolerability: Results of a 1-Year Clinical Trial in Patients with Mild-to-Moderate Alzheimer's Disease

By Cummings Jeffrey L.

Clinical Drug Investigation, Vol. 30, Iss. 1, 2010-01 ,pp. : 41-49

Adis International

Access to resources Recommend Favorite

Apolipoprotein E4 (ApoE4) genotype and/or gender do not appear to predict a response to donepezil in patients with mild-to-moderate Alzheimer's disease

Inpharma, Vol. 1, Iss. 1248, 2000-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Nicergoline in the Treatment of Mild-to-Moderate Alzheimer's Disease: A European Multicentre Trial

By Winblad B.

Clinical Drug Investigation, Vol. 21, Iss. 9, 2001-09 ,pp. : 621-632

Adis International

Access to resources Recommend Favorite

Donepezil a smart choice for mild-to-moderate AD in the UK

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 603, 2010-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimer's Disease: A UK Evaluation Using Discrete-Event Simulation

By Getsios Denis

PharmacoEconomics, Vol. 28, Iss. 5, 2010-05 ,pp. : 411-427

Adis International

Access to resources Recommend Favorite